LGMD2I

Clinical trials for LGMD2I explained in plain language.

Never miss a new study

Get alerted when new LGMD2I trials appear

Sign up with your email to follow new studies for LGMD2I, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet finished but already full! 1 Completed 1

Experimental drug targets root cause of rare muscle-wasting disease

Disease control Ongoing

This study tests an experimental drug, BBP-418, in people with limb girdle muscular dystrophy type 2I (LGMD2I), a rare genetic condition that causes progressive muscle weakness. The drug aims to fix a molecular defect by helping a faulty enzyme work better. The trial includes bot…

Matched conditions: LGMD2I

Phase: PHASE2 • Sponsor: ML Bio Solutions, Inc. • Aim: Disease control

Last updated Jul 23, 2026 00:00 UTC

LGMD2I

Get alerted when new LGMD2I trials appear

Experimental drug targets root cause of rare muscle-wasting disease